SHORT MINI-FUTURE - NOVO-NORDISK B | Market Closed - Boerse Frankfurt Warrants 11:24:48 28/05/2024 pm IST | ||
| 2.5 EUR | +6.38% |
|
| Current month | -5.66% | ||
| 1 month | -11.03% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.5 | +6.38% |
| 27/24/27 | 2.35 | +7.31% |
| 24/24/24 | 2.19 | +2.82% |
| 23/24/23 | 2.13 | -10.13% |
| 22/24/22 | 2.37 | +3.49% |
Real-time Boerse Frankfurt Warrants
Last update May 28, 2024 at 11:24 pm IST
More quotesStatic data
| Product type | Knock-Out con Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Vontobel
|
| WKN | VD1JLS |
| ISIN | DE000VD1JLS7 |
| Date issued | 05/03/2024 |
| Strike | 1,104 kr |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 3.28 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.56 € |
|---|---|
| Lowest since issue | 2.13 € |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
915.7
DKK
Average target price
909.2
DKK
Spread / Average Target
-0.71%
- Stock Market
- Certificates
- Certificat
